Redundancy: A critical obstacle to improving cancer therapy

Cancer Research

Volumn 75, Issue 5, 2015, Pages 808-812

  Lavi, Orit ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ANIMAL; DRUG RESISTANCE; HUMAN; MOUSE; NEOPLASMS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; HUMANS; MICE; NEOPLASMS;

EID: 84928703381     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-3256     Document Type: Review

References (45)

1. Alon U. An introduction to systems biology: design principles of biological circuits. London, UK: CRC Press; 2006.
2. Hastie T, Tibshirani R, Friedman J. The elements of statistical learning: data mining, inference, and prediction. 2nd ed. New York: Springer Science; 2009.
3. Murray JD. Mathematical biology: I. An introduction (interdisciplinary applied mathematics) (Part 1). Berlin: Springer; 2002.
4. Wang EE. Cancer systems biology. Boca Raton, FL: CRC Press; 2010.
5. Ding L, Wendl MC, McMichael JF, Raphael BJ. Expanding the computational toolbox for mining cancer genomes. Nat Rev Genet 2014;15:556-70.
6. Lavi O, Gottesman MM, Levy D. The dynamics of drug resistance: a mathematical perspective. Drug Resist Updat 2012;15:90-7.
7. Pe'er D, Hacohen N. Principles and strategies for developing network models in cancer. Cell 2011;144:864-73.
8. Du W, Elemento O. Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies. Oncogene 2014 Sep. 15. [Epub ahead of print].
9. Box G E P, Draper NR. Empirical model-building and response surfaces. New York: John Wiley & Sons; 1987.
10. Jia J, Zhu F, Ma X, Cao Z, Li Y, Chen YZ. Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov 2009;8:111-28.
11. Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 2006;5:1136-44.
12. Qadir M, O'Loughlin KL, Fricke SM, Williamson NA, Greco WR, Minderman H, et al. Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clin Cancer Res 2005;11:2320-6.
13. Lavi O, Greene JM, Levy D, Gottesman MM. Simplifying the complexity of resistance heterogeneity in metastasis. Trends Mol Med 2014;20:129-36.
14. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2189-99.
15. Boussiotis VA. Somatic mutations and immunotherapy outcome with CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2230-2.
16. Gasch AP, Spellman PT, Kao CM, Carmel-Harel O, Eisen MB, Storz G, et al. Genomic expression programs in the response of yeast cells to environmental changes. Mol Biol Cell 2000;11:4241-57.
17. Ideker T, Thorsson V, Ranish JA, Christmas R, Buhler J, Eng JK, et al. Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. Science 2001;292:929-34.
18. Fong SS, Palsson BO. Metabolic gene-deletion strains of Escherichia coli evolve to computationally predicted growth phenotypes. Nat Genet 2004;36:1056-8.
19. Daran-Lapujade P, Jansen ML, Daran JM, van Gulik W, de Winde JH, Pronk JT. Role of transcriptional regulation in controlling fluxes in central carbon metabolism of Saccharomyces cerevisiae. A chemostat culture study. J Biol Chem 2004;279:9125-38.
20. Gillet JP, Gottesman MM. Mechanisms of multidrug resistance in cancer. Methods Mol Biol 2010;596:47-76.
21. Kitano H. Biological robustness. Nat Rev Genet 2004;5:826-37.
22. Wang Z, Zhang J. Abundant indispensable redundancies in cellular metabolic networks. Genome Biol Evol 2009;1:23-33.
23. Taniguchi T. Cytokine signaling through nonreceptor protein tyrosine kinases. Science 1995;268:251-5.
24. Nowak MA, Boerlijst MC, Cooke J, Smith JM. Evolution of genetic redundancy. Nature 1997;388:167-71.
25. Brookfield JF. Genetic redundancy. Adv Genet 1997;36:137-55.
26. Harrison R, Papp B, Pal C, Oliver SG, Delneri D. Plasticity of genetic interactions in metabolic networks of yeast. Proc Natl Acad Sci U S A 2007;104:2307-12.
27. Laney JD, Biggin MD. Redundant control of ultrabithorax by zeste involves functional levels of zeste protein binding at the ultrabithorax promoter. Development 1996;122:2303-11.
28. Saga Y, Yagi T, Ikawa Y, Sakakura T, Aizawa S. Mice develop normally without tenascin. Genes Dev 1992;6:1821-31.
29. Polager S, Ginsberg D. p53 and E2f: partners in life and death. Nat Rev Cancer 2009;9:738-48.
30. Wu L, Timmers C, Maiti B, Saavedra HI, Sang L, Chong GT, et al. The E2F1-3 transcription factors are essential for cellular proliferation. Nature 2001;414:457-62.
31. Sherr CJ, Roberts JM. Living with or without cyclins and cyclin-dependent kinases. Genes Dev 2004;18:2699-711.
32. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5:219-34.
33. Singhal SS, Singhal J, Nair MP, Lacko AG, Awasthi YC, Awasthi S. Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol 2007;30:717-25.
34. Milo R, Shen-Orr S, Itzkovitz S, Kashtan N, Chklovskii D, Alon U. Network motifs: simple building blocks of complex networks. Science 2002;298:824-7.
35. Lavi O, Ginsberg D, Louzoun Y. Regulation of modular Cyclin and CDK feedback loops by an E2F transcription oscillator in the mammalian cell cycle. Math Biosci Eng 2011;8:445-61.
36. Eberlin LS, Tibshirani RJ, Zhang J, Longacre TA, Berry GJ, Bingham DB, et al. Molecular assessment of surgical-resection margins of gastric cancer by mass-spectrometric imaging. Proc Natl Acad Sci U S A 2014;111:2436-41.
37. Budczies J, Brockmoller SF, Muller BM, Barupal DK, Richter-Ehrenstein C, Kleine-Tebbe A, et al. Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: alterations in glutamine and beta-alanine metabolism. J Proteomics 2013;94:279-88.
38. Cavill R, Kamburov A, Ellis JK, Athersuch TJ, Blagrove MS, Herwig R, et al. Consensus-phenotype integration of transcriptomic and metabolomic data implies a role for metabolism in the chemosensitivity of tumour cells. PLoS Comput Biol 2011;7:e1001113.
39. Lehar J, Krueger AS, Avery W, Heilbut AM, Johansen LM, Price ER, et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol 2009;27:659-66.
40. Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 1995;47:331-85.
41. Cokol M, Chua HN, Tasan M, Mutlu B, Weinstein ZB, Suzuki Y, et al. Systematic exploration of synergistic drug pairs. Mol Syst Biol 2011;7:544.
42. Huang S, Kauffman S. How to escape the cancer attractor: rationale and limitations of multi-target drugs. Semin Cancer Biol 2013;23:270-8.
43. Jerby L, Ruppin E. Predicting drug targets and biomarkers of cancer via genome-scale metabolic modeling. Clin Cancer Res 2012;18:5572-84.
44. Lenski RE, Barrick JE, Ofria C. Balancing robustness and evolvability. PLoS Biol 2006;4:e428.
45. Gibson G, Wagner G. Canalization in evolutionary genetics: a stabilizing theory? Bioessays 2000;22:372-80.